ASND - Ascendis Pharma A/S

QQQ $ 473.83 $ 0.25 (0.05 %)

DIA $ 417.12 $ -0.12 (-0.03 %)

SPY $ 563.14 $ 0.23 (0.04 %)

TLT $ 100.82 $ -0.49 (-0.48 %)

GLD $ 237.35 $ -1.32 (-0.55 %)

Previous Close

$ 146.59

Open

$ 140.76

Bid

$ 146.50 x 100

Ask

-- x --

Day's Range

$ 138.88 - $ 148.40

52 Week Range

$ 85.29 - $ 161.00

Volume

1,993,211

Average Volume

Market Cap

8.46B

Beta (5Y Monthly)

$ 0.71

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wells Fargo Maintains Overweight on Ascend...
09/17/2024 15:42:18

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from...

Citigroup Maintains Buy on Ascendis Pharma...
09/17/2024 15:21:30

Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $178 to...

Evercore ISI Group Maintains Outperform on...
09/17/2024 13:57:56

Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price targ...

Oppenheimer Reiterates Outperform on Ascen...
09/17/2024 13:49:54

Oppenheimer analyst Leland Gershell reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target f...

Goldman Sachs Maintains Buy on Ascendis Ph...
09/17/2024 13:26:25

Goldman Sachs analyst Paul Choi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $180 to ...

despite-being-first-mover-biomarins-voxzogo-for-dwarfism-to-face-pressure-from-ascendis-candidate-in-near-term

Despite Being First Mover, BioMarin's Voxz...
09/16/2024 19:12:28

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by l...

Crude Oil Surges Over 1%; Instil Bio Share...
09/16/2024 16:31:33

ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year

Ascendis Pharma's Rare Dwarfism Candidate ...
09/16/2024 16:18:34

Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia.

alcoa-lattice-semiconductor-stratasys-and-other-big-stocks-moving-higher-on-monday

Alcoa, Lattice Semiconductor, Stratasys An...
09/16/2024 14:03:58

Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 12:22:09

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $170 price target.

Ascendis Pharma Announced Topline Data Fro...
09/16/2024 11:08:12

Ascendis To Present First Results From Pla...
09/13/2024 12:31:42

Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 β...

Ascendis Pharma Says FDA Granted Orphan Dr...
09/11/2024 21:39:15

YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once daily, designed to provide continuous exposure to...

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:13:56

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $170 price target.

Ascendis Pharma shares are trading higher ...
09/05/2024 13:55:41

Oppenheimer Upgrades Ascendis Pharma to Ou...
09/05/2024 12:04:29

Oppenheimer analyst Leland Gershell upgrades Ascendis Pharma (NASDAQ:ASND) from Perform to Outperform and announces $180 pri...

Citigroup Maintains Buy on Ascendis Pharma...
09/05/2024 00:09:11

Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $193 to...

JP Morgan Maintains Overweight on Ascendis...
09/04/2024 22:23:19

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $17...

ascendis-pharma-faces-challenges-with-skytrofa-and-yorvipath-pricing-analysts-weigh-in

Ascendis Pharma Faces Challenges With Skyt...
09/04/2024 21:02:35

Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included...

TD Cowen Maintains Buy on Ascendis Pharma,...
09/04/2024 17:18:01

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $175 to $157.